The Influence of Corneal Thickness on Progression of Hypertensive Glaucoma

Lešták, Jan; Rozsíval, P

doi:10.4172/2155-9570.1000245

Cited by 7 publications

(6 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also confirmed this in our study, where we monitored the progression of changes in the visual fields in compensated glaucoma eyes over a 5-year period. We found that the greater the baseline perimeter changes were, the greater was their progression in 5 years [37].…”

Section: Electrophysiology In Hypertensive Glaucomamentioning

confidence: 63%

Neuropathology in Hypertensive Glaucoma

Lešták¹,

Fus²

2021

Ocular Hypertension - The Knowns and Unknowns

View full text Add to dashboard Cite

Hypertensive glaucoma is still defined as a disease where, at high intraocular pressure, retinal ganglion cell axons are impaired with excavation at the optic disc and changes in the visual field. In single cases, the study highlights the importance of knowledge of neuropathology not only at the level of the retina but the entire visual pathway, including the visual centres in the brain. It uses the issue of neurotransmission in the visual analyser and its pathology, but mainly the results of electrophysiological examinations and functional imaging of the brain using Positron Emission Tomography and Functional Magnetic Resonance. It does not overlook the imaging methods of the eye (nerve fibre layer, vessel density). On the basis of this information, therapy is recommended as well.

show abstract

Section: Electrophysiology In Hypertensive Glaucomamentioning

confidence: 63%

Neuropathology in Hypertensive Glaucoma

Lešták¹,

Fus²

2021

Ocular Hypertension - The Knowns and Unknowns

View full text Add to dashboard Cite

show abstract

“…We also confirmed this in the study in which we observed progression of changes in the visual fields in the compensated glaucoma eyes in a five-year period. We found that the bigger the initial perimetric changes were, the bigger was their progression in five years (34).…”

Section: Determining the Level And Depth Of Damagementioning

confidence: 70%

Neuroprotection in glaucoma‑electrophysiology (Review)

Lešták

Fus

2020

Exp Ther Med

View full text Add to dashboard Cite

Hypertensive glaucoma is defined as a group of diseases with progressive loss of the neuroretinal margin of the optic disc that causes characteristic degenerative optic neuropathy. The present study provided an updated summary of the physiology and pathology of neurotransmission in the visual path, with the focus on glaucoma. The results of positron emission tomography, functional magnetic resonance imaging and mainly electrophysiological methods demonstrated pathogenesis of nerve cell damage in the visual pathway. Based on these conclusions, neuroprotection in glaucoma was proposed. This consists mainly of the reduction of the intraocular pressure. It is followed by a decrease of glutamate in the synaptic cleft and blockade of its binding to the NMDA receptors. The supply of energy substrates to altered nerve cells is also indispensable. Therapy should be systemic due to impairment of the complete visual path.

show abstract

“…To eliminate the influence of age, gender, CCT, and various changes in the visual field, we set up approximately similar homogeneous groups. A greater progression of changes in visual fields was seen in thin corneas [14]. We know that testing the visual field with a visual field analyzer is not the most sensitive functional examination for glaucoma of the visual analyzer.…”

Section: Discussionmentioning

confidence: 97%

Comparison of b-Blockers and Prostaglandins Treatments in Primary Open-Angle Glaucoma

Lešták¹,

Pitrová²,

Rozsíval³

2013

J Clin Exp Ophthalmol

View full text Add to dashboard Cite

Objectives: Retrospective study to compare long-term effects of treatment with β-blockers and prostaglandins by assessing changes in visual fields. Methods and Patients: The group included 60 patients of approximately the same age (61 and 62 year olds), with the same changes in the visual field and the same central corneal thickness (556 µm), of which 30 were treated with β-blockers (18 females and 12 males) and 30 with prostaglandins (15 females and 15 males). There were no changes in medication in the course of treatment. During the follow-ups, the intraocular pressure was in the range 10 to 20 mmHg. We evaluated the changes in visual fields (pattern defects) at the last examination in 2012. The results were compared with findings in visual fields from 2005. No subject had any eye or systemic disease that could affect changes in the visual field. Corneal pachymetry was performed with a Tomey SP-100 ultrasound device. The visual field was examined by static perimetry using a MEDMONT M 700 device with a fast threshold glaucoma program. For comparison of the two groups treated with β-blockers and prostaglandins, we used the Mann-Whitney´s test. For comparison of treatment with β-blockers timolol, carteolol, betaxozol and vistagan, we used the non-parametric Kruskal-Wallis´ test, and subsequently to compare therapies with prostaglandins latanoprost and bimatoprost, we used the non-parametric two-sided Mann-Whitney´s test. Results: With statistical analysis, we have found neither changes between β-blockers and prostaglandins treatments (p=0.395 to 0.836) nor differences between different beta-blockers (p=0.495 to 0.576). Similarly, we found no statistically significant changes in either treatment with bimatoprost and latanoprost (0.575 to 0.965). Conclusion: Our results in the follow-up period of seven years showed no difference in the functional changing of visual field between the treatments with β-blockers and prostaglandins.

show abstract

The Influence of Corneal Thickness on Progression of Hypertensive Glaucoma

Cited by 7 publications

References 16 publications

Neuropathology in Hypertensive Glaucoma

Neuropathology in Hypertensive Glaucoma

Neuroprotection in glaucoma‑electrophysiology (Review)

Comparison of b-Blockers and Prostaglandins Treatments in Primary Open-Angle Glaucoma

Contact Info

Product

Resources

About